대한치매학회지 (Dementia and Neurocognitive Disorders)

대한치매학회 (Korean Dementia Association)
권호 표지
DOI QR코드

DOI QR Code

Association Between Persistent Treatment of Alzheimer's Dementia and Osteoporosis Using a Common Data Model

  • Seonhwa Hwang (Kangwon National University School of Medicine) ;
  • Yong Gwon Soung (Department of Neurology, Kangwon National University Hospital) ;
  • Seong Uk Kang (Department of Convergence Security, Kangwon National University) ;
  • Donghan Yu (Big Data Department, Health Insurance Review & Assessment Service) ;
  • Haeran Baek (Big Data Department, Health Insurance Review & Assessment Service) ;
  • Jae-Won Jang (Kangwon National University School of Medicine)
  • 투고 : 2023.06.29
  • 심사 : 2023.10.03
  • 발행 : 2023.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Purpose: As it becomes an aging society, interest in senile diseases is increasing. Alzheimer's dementia (AD) and osteoporosis are representative senile diseases. Various studies have reported that AD and osteoporosis share many risk factors that affect each other's incidence. This aimed to determine if active medication treatment of AD could affect the development of osteoporosis. Methods: The Health Insurance Review and Assessment Service provided data consisting of diagnosis, demographics, prescription drug, procedures, medical materials, and healthcare resources. In this study, data of all AD patients in South Korea who were registered under the national health insurance system were obtained. The cohort underwent conversion to an Observational Medical Outcomes Partnership-Common Data Model version 5 format. Results: This study included 11,355 individuals in the good persistent group and an equal number of 11,355 individuals in the poor persistent group from the National Health Claims database for AD drug treatment. In primary analysis, the risk of osteoporosis was significantly higher in the poor persistence group than in the good persistence group (hazard ratio, 1.20 [95% confidence interval, 1.09-1.32]; p<0.001). Conclusions: We found that the good persistence group treated with anti-dementia drugs for AD was associated with a significant lower risk of osteoporosis in this nationwide study. Further studies are needed to clarify the pathophysiological link in patients with two chronic diseases.

키워드

과제정보

We would like to thank the Health Insurance Review and Assessment Service for assistance in providing and analyzing data.

참고문헌

  1. Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 2017;317:2305-2316. 
  2. Kwon MJ, Kim JH, Kim JH, Cho SJ, Nam ES, Choi HG. The occurrence of Alzheimer's disease and Parkinson's disease in individuals with osteoporosis: a longitudinal follow-up study using a national health screening database in Korea. Front Aging Neurosci 2021;13:786337. 
  3. Fehsel K, Christl J. Comorbidity of osteoporosis and Alzheimer's disease: is 'AKT'-ing on cellular glucose uptake the missing link? Ageing Res Rev 2022;76:101592. 
  4. Chen YH, Lo RY. Alzheimer's disease and osteoporosis. Ci Ji Yi Xue Za Zhi 2017;29:138-142. 
  5. Chang KH, Chung CJ, Lin CL, Sung FC, Wu TN, Kao CH. Increased risk of dementia in patients with osteoporosis: a population-based retrospective cohort analysis. Age (Dordr) 2014;36:967-975. 
  6. Buchner DM, Larson EB. Falls and fractures in patients with Alzheimer-type dementia. JAMA 1987;257:1492-1495. 
  7. Tysiewicz-Dudek M, Pietraszkiewicz F, Drozdzowska B. Alzheimer's disease and osteoporosis: common risk factors or one condition predisposing to the other? Ortop Traumatol Rehabil 2008;10:315-323. 
  8. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer's disease. N Engl J Med 2023;388:9-21. 
  9. Park KH, Yang Y, Chen C, Shim YS, Domingueze JC, Lee CN, et al. Discontinuation rate of newly prescribed donepezil in Alzheimer's disease patients in Asia. J Clin Neurol 2021;17:376-384. 
  10. Kim HJ, Shim YS, Park KH, Lee CN, Jung S, Yoon SJ, et al. Impact of an education program for caregivers of patients with Alzheimer's disease on treatment discontinuation and compliance in Korea. J Clin Neurol 2021;17:368-375. 
  11. Ogunwale AN, Colon-Emeric CS, Sloane R, Adler RA, Lyles KW, Lee RH. Acetylcholinesterase inhibitors are associated with reduced fracture risk among older veterans with dementia. J Bone Miner Res 2020;35:440-445.
  12. Lee MH, Choi JW, Lee J, Shin A, Oh SM, Jung SJ, et al. Trends in prescriptions for sedative-hypnotics among Korean adults: a nationwide prescription database study for 2011-2015. Soc Psychiatry Psychiatr Epidemiol 2019;54:477-484. 
  13. You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, et al. Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA 2020;324:1640-1650. 
  14. Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015;216:574-578. 
  15. Yang Y, Zhou X, Gao S, Lin H, Xie Y, Feng Y, et al. Evaluation of electronic healthcare databases for postmarketing drug safety surveillance and pharmacoepidemiology in China. Drug Saf 2018;41:125-137. 
  16. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012;19:54-60. 
  17. Sato T, Enoki Y, Sakamoto Y, Yokota K, Okubo M, Matsumoto M, et al. Donepezil prevents RANK-induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase. Heliyon (Lond) 2015;1:e00013. 
  18. Friedland RP, Fritsch T, Smyth KA, Koss E, Lerner AJ, Chen CH, et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc Natl Acad Sci U S A 2001;98:3440-3445. 
  19. Rogers RS, Hinton PS. Bone loading during young adulthood predicts bone mineral density in physically active, middle-aged men. Phys Sportsmed 2010;38:146-155. 
  20. Baxter-Jones AD, Kontulainen SA, Faulkner RA, Bailey DA. A longitudinal study of the relationship of physical activity to bone mineral accrual from adolescence to young adulthood. Bone 2008;43:1101-1107. 
  21. Nilsson M, Ohlsson C, Mellstrom D, Lorentzon M. Previous sport activity during childhood and adolescence is associated with increased cortical bone size in young adult men. J Bone Miner Res 2009;24:125-33. 
  22. Michaelsson K, Olofsson H, Jensevik K, Larsson S, Mallmin H, Berglund L, et al. Leisure physical activity and the risk of fracture in men. PLoS Med 2007;4:e199. 
  23. Van Langendonck L, Lefevre J, Claessens AL, Thomis M, Philippaerts R, Delvaux K, et al. Influence of participation in high-impact sports during adolescence and adulthood on bone mineral density in middle-aged men: a 27-year follow-up study. Am J Epidemiol 2003;158:525-533. 
  24. Carter MI, Hinton PS. Physical activity and bone health. Mo Med 2014;111:59-64. 
  25. Nordstrom A, Olsson T, Nordstrom P. Bone gained from physical activity and lost through detraining: a longitudinal study in young males. Osteoporos Int 2005;16:835-841. 
  26. Nordstrom A, Olsson T, Nordstrom P. Sustained benefits from previous physical activity on bone mineral density in males. J Clin Endocrinol Metab 2006;91:2600-2604.